Table 2.
Latency period by primary site among patients with sALL and a known primary site according to the frequency of 1M
| Primary site | N (%) | Mean (SD) | Median (Q1–Q3) | Range |
|---|---|---|---|---|
| All sites | 772 | 72.8 (61.6) | 60.0 (24.0–101.0) | 2–423 |
| Breast | 138 (17.9%) | 85.9 (72.4) | 67.0 (31.0–114.0) | 4–423 |
| Prostate | 134 (17.4%) | 73.1 (53.9) | 66.5 (29.0–94.0) | 2–272 |
| Other | 112 (14.5%) | 69.4 (62.5) | 55.5 (19.0–94.0) | 2–308 |
| Other Leukemiaa | 87 (11.3%) | 46.0 (46.5) | 28.0 (13.0–65.0) | 2–253 |
| Lymphomab | 83 (10.8%) | 64.0 (63.2) | 42.0 (13.0–104.0) | 2–271 |
| Colorectal | 53 (6.9%) | 82.5 (70.3) | 68.0 (33.0–103.0) | 3–282 |
| Lung | 33 (4.3%) | 45.9 (47.3) | 36.0 (15.0–53.0) | 2–209 |
| Thyroid | 29 (3.8%) | 85.0 (36.3) | 86.0 (54.0–102.0) | 22–165 |
| Bladder | 24 (3.1%) | 98.1 (67.8) | 81.0 (53.5–143.0) | 6–287 |
| Myeloma | 21 (2.7%) | 76.5 (41.7) | 70.0 (61.0–82.0) | 19–214 |
| Melanoma of the skin | 20 (2.6%) | 77.9 (57.1) | 69.5 (39.0–96.5) | 2–224 |
| Kidney | 20 (2.6%) | 84.9 (51.0) | 67.5 (50.5–129.0) | 3–169 |
| Ovary | 16 (2.1%) | 103.9 (74.1) | 92.0 (42.0–150.5) | 15–285 |
| Brain | 2 (0.3%) | 114.5 (113.8) | 114.5 (34.0–195.0) | 34–195 |
1M, primary malignancies; N, number; Q1, first quartile; Q3, third quartile; sALL, second primary acute lymphoblastic leukemia; SD, standard deviation.
a
Other types of leukemia included chronic lymphocytic leukemia, other nonacute lymphocytic leukemia, acute myeloid leukemia, acute monocytic leukemia, chronic myeloid leukemia, other myeloid/monocytic leukemia, acute lymphocytic leukemia, acute undifferentiated leukemia, acute phenotypic leukemia, mixed phenotype acute leukemia, and acute panmyelosis with myelofibrosis.
b
Lymphoma included Hodgkin – nodal, Hodgkin – extra nodal, NHL – nodal, and NHL – extra nodal.